NCT06014255View on ClinicalTrials.gov

Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

219

Participants

Timeline

Start Date

February 16, 2024

Primary Completion Date

March 1, 2029

Study Completion Date

March 1, 2029

Conditions
Prostate Cancer
Interventions
DRUG

Enoblituzumab

Enoblituzumab 15mg/kg IV (in the vein) every 2 weeks for 12 weeks prior to radical prostatectomy on day 84.

OTHER

Standard of Care

Radical prostatectomy within 4-8 weeks of randomization.

Trial Locations (5)

21205

RECRUITING

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

55414

NOT_YET_RECRUITING

University of Minnesota, Minneapolis

55905

RECRUITING

Mayo Clinic, Rochester

60611

RECRUITING

Northewestern University, Chicago

68130

NOT_YET_RECRUITING

XCancer - Omaha, LLC, Omaha

Sponsors

Collaborators (1)

MacroGenics
All Listed Sponsors
collaborator

MacroGenics

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT06014255 - Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer | Biotech Hunter | Biotech Hunter